
ApoGen increases 2016 Series A funding round to $11 million
Company draws $4 million in additional funding from Merck KGaA's venture capital arm and other investors.
Company draws $4 million in additional funding from Merck KGaA's venture capital arm and other investors.
Company seeks to block components of reactivated programmed cell death process implicated in Alzheimer's disease.